Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) May 14, 2020
NASCENT BIOTECH, INC.
(Exact name of registrant as specified in its charter)
Nevada
000-55299
46-5001940
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
6330 Nancy Ridge Dr Suite 105, San Diego CA.
92121
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code (612) 961-5656
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01 Material Definitive Contract.
On April 30, 2020, Nascent Biotech Inc. (the “Company”) entered into a research collaboration agreement with Manhattan BioSolutions, Inc. (“MBI”), an unrelated third party, to initiate a vaccine program for the potential prevention of COVID-19 or other viral infections.
Under the terms of the agreement the Company will fund the project through equity of $200,000 and receive an exclusive royalty-based license on any intellectual property discovered for the usage with the prevention of coronaviruses.
Item 2.03 Creation of Direct Financial Obligation or an Obligation under an Off Balance Sheet Arrangement of a Registrant.
The information provided in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
NASCENT BIOTECH, INC.
Date: May 14, 2020
/s/ Sean Carrick
Sean Carrick
President
3
We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.
